VANCOUVER, British Columbia–(BUSINESS WIRE)–April 13, 2005–MIV Therapeutics Inc., a developer of next-generation biocompatible stent coatings and drug delivery technologies, announced today that it will conduct a presentation about its proprietary biocompatible medical device coating technology at the 4th European Symposium of Vascular Biomaterials in Strasbourg, France, scheduled for May 11-13.
A lecture authored by MIVT scientists, titled, “Progress in Development Of Composite Calcium Phosphate Coatings For Stents,” has been accepted for public presentation at the Symposium. The lecture discusses the applications and early laboratory results of MIVT’s proprietary hydroxyapatite (HAp) coatings for vascular stents and other medical devices, which has been shown to provide superior biocompatibility and safety, as well as additional functionality for drug-eluting applications.
The synopsis of the lecture reads: “We have demonstrated the viability of the sol-gel process to coat thin films of HAp on stent surfaces. Preliminary animal studies indicate excellent response of vascular tissue to the SG-HAp-coated stent surface. The processing and characterization results, as well as the results of preliminary animal studies, are extremely encouraging.”
The lecture was co-authored by Arc Rajtar, MIVT’s Vice President of Operations, M. Lien, D. Smith, D. Hakimi, Q. Yang, M. Tsui, and Dr. Tom Troczynski, Vice President of Coatings for MIVT, and Professor at the University of British Columbia, who will also deliver this presentation at the Symposium.
“Presentation at the 4th European Symposium of Vascular Biomaterials is intended as an introduction of our proprietary process for HAp coatings for cardiovascular stents to the broad community of European clinicians, researchers and businesses,” said Alan Lindsay, Chairman and CEO of MIV Therapeutics. “By presenting an important milestone Lecture at the 4th European Symposium of Vascular Biomaterials in Strasbourg we will update the audience on the state of the art of the technology and on the progress and exceptionally encouraging outcomes of the pre-clinical studies.”
Dr. Tom Troczynski added, “The European Symposium of Vascular Biomaterials in Strasbourg is one of the most prestigious events in this area in the world. All submissions to the Symposium undergo rigorous review and selection process. MIV Therapeutics will be presenting our newest results on the technology of the coatings, as well as the first glimpses of preliminary results of comprehensive pre-clinical animal studies, which are being conducted at the present time.”